Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...

It was a busy week for the biotech sector, as the fourth-quarter earnings season is in full swing. While Gilead Sciences, Inc. GILD gained following the earnings beat and upbeat guidance for 2025, ...

Q4 2024 Management View CEO Kevin Ali highlighted full-year 2024 revenue of $6.4 billion, representing a 3% growth rate at constant currency. All three franchises posted three consecutive years of ...

Moderna's Q4 earnings due Feb 14: analysts predict revenue decline & $2.73 loss. Explore vaccine demand, pipeline prospects, and stock outlook.

In Q4 of 2024, Article 8 funds netted an estimated EUR 51.9 billion of net new money, the highest inflows of the year, supported by increased subscriptions into fixed-income funds. This report ...